[팜뉴스=이권구 기자] Prestige Biopharma (CEO Park So-yeon) signed an MOU with Vaxine, an Australian vaccine development company, on the 29th to supply a COVID-19 vaccine and cooperate in the development of a combined corona-flu vaccine.
According to the company, the COVID-19 vaccine ‘Spikogen’ developed by Park Shin is a vaccine containing recombinant virus protein and immune enhancer. Is expected. Spicogen is currently under review for use approval by the Australian Food and Drug Administration, and was approved for emergency use in the Middle East in October last year.
This MOU also includes cooperation in the joint development of a combined vaccine that can prevent both coronavirus and influenza at the same time. The two companies plan to actively cooperate in joint research on economical and safe recombinant protein vaccines for various infectious diseases by utilizing Park Shin’s long experience in vaccine development.
Shin Park, CEO of Flinders Medical University, Australia, and Professor Nikolai Petrovsky, who is considered one of the best scientists in the field of vaccines. has been devoted to development. He conducted the world’s first H1N1 influenza vaccine clinical trial in 2009, and also succeeded in developing SARS and MERS vaccines.
CEO Nikolai Petrovsky said, “We plan to actively cooperate in research and development of the H7N9 type avian influenza vaccine and Japanese encephalitis vaccine, as well as the COVID-19 vaccine and the corona-flu combined vaccine. “There is an urgent need to develop a vaccine as there are cases of infection and deaths in Australia,” he said.
Park So-yeon, CEO of Prestige Biopa, said, “Through a business agreement with Park Shin, a vaccine development company that has been conducting numerous vaccine projects for a long time with the US government, we plan to carry out various vaccine development projects in preparation for the advent of the endemic corona virus.” “We will continue to cooperate with leading global vaccine research institutes and companies, centering on the Busan Innovative Discovery Center, to create synergies and carry out competitive vaccine development and consignment production projects,” he said.